Complex of antibody and IL-2 (Interleukin-2) and application thereof

Abstract

The invention relates to the technical field of antibodies, in particular to a complex of an antibody and IL-2 and application of the complex. The present invention provides a complex of an antibody and IL-2, comprising: an immune checkpoint antibody and an IL15R [alpha] receptor domain covalently linked, and an IL-2 / 15 chimera (S-unit molecule) or a variant thereof non-covalently complexed with the IL15R [alpha] receptor domain. By means of the creative design, IL-2 molecules are gradually dissociated from the complex to achieve a short half-life period, and an immune checkpoint antibody achieves a long half-life period due to the fact that an Fc structural domain is combined with FcRn circulation. As a result, the half-lives and administration dosages of the two molecules can be matched to each other.

Description

Technical Field

[0001] The present invention relates to the field of antibody technology, and in particular to a complex of an antibody and IL-2 and an application thereof. Background Art

[0002] Cancer is a disease that seriously endangers human health and lifespan. It is characterized by the excessive growth of malignant tumor cells and can cause a variety of complications. Since the beginning of the 21st century, tumor immunotherapy represented by PD-1 / PD-L1 has rewritten the history of tumor immunotherapy and achieved great success. The development of new tumor immunotherapy targets and combination drug regimens has become one of the biggest hotspots in the development of new drugs in China and even in the world. However, with the accumulation of more clinical data for PD-1 / PD-L1 antibodies such as Keytruda and Opdivo, the limitations of PD-1 / PD-L1 antibodies in the treatment of solid tumors are becoming increasingly apparent.

[0003] As a naturally occurring immune cell agonist, cytokines have great potential in enhancing the overall immune system and anti-tumor effects. However, the huge toxic side effects that accompany them greatly restrict the clinical use of such molecules. Therefore, while cytokines represented by modified IL-2 have become the top priority of many pharmaceutical companies' pipeline layout, various design ideas for reducing toxicity and enhancing efficacy of IL-2 and IL-15 have been disclosed. In 2022, Chinese invention CN114380919A disclosed a new IL-2 design scheme, in which the sequence responsible for binding to CD25 (i.e., IL-2Rα) and some other sequences in the IL-2 molecule are replaced with corresponding sequences in IL-15 to form a new cytokine (S-unit molecule), which is combined with the CD215 fragment (IL-15Rα) to form a stable complex (L-unit molecule). The complex L-unit is a new cytokine with strong cytological activity and anti-tumor activity.

[0004] In 2021, Roche reported that the fusion protein of PD-1 antibody and IL-2 mutant (IL-2v) has stronger anti-tumor activity than PD-1 antibody alone and can overcome immune checkpoint tolerance. In September 2022, Roche again published a study titled "PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+T cells" in Nature. The study confirmed in multiple in vivo tumor efficacy models that compared with PD-1 antibody and IL-2v alone and in combination therapy, PD1-IL2v fusion protein has a stronger ability to inhibit tumor growth, has better survival benefits, and significantly expands the number of antigen-specific PD-1+TCF-1+ stem-like T cells. Although both from the biological mechanism and preclinical efficacy experiments, it has been shown that PD1-IL2v fusion protein has stronger anti-tumor activity than PD-1 or IL-2v alone, but there are many problems in the actual drug molecule design. On the one hand, there is a huge difference in the half-life of PD-1 antibody and IL-2 in the human body. According to literature reports, the half-life of PD-1 antibody in the human body can be as long as 20 days (Teresa C. Longoria et al., Expert Opin Drug Metab Toxicol. 2016 Oct; 12: 1247-1253.), however, the half-life of aldesleukin (wild-type IL-2) in the human body is only about 5 to 7 minutes (MT Lotze et al., J Immunol. 1985 Jan; 134(1): 157-66.), which is more than 3,000 times different, and is not suitable for direct development as a fusion protein. On the other hand, the dosage of PD-1 antibodies and IL-2 molecules in clinical applications is also very different. The clinical dosage of PD-1 antibody Keytruda is 200 to 400 mg each time, which is approximately 2 to 5 mg / kg, while the dosage of wild-type IL-2 aldesleukin is only 0.037 mg / kg. The difference between the two is 50 to 100 times, and they are also not suitable for direct development as fusion proteins.

[0005] Therefore, there is a need in the art for a product that can match and unify the half-life and dosage of immune checkpoint antibodies and cytokines. Summary of the invention

[0006] In view of this, in a first aspect, the present invention provides a complex of an antibody and IL-2, comprising:

[0007] Covalently linked immune checkpoint antibodies and IL15Rα receptor domains, and

[0008] IL-2 / 15 chimera (S-unit molecule) or variants thereof non-covalently complexed with the IL15Rα receptor domain.

[0009] In some specific embodiments, the IL-2 / 15 chimera comprises replacing the region of the IL-2 molecule that mediates the binding of the IL-2 molecule to IL2Rα with the region of the IL-15 molecule that mediates the binding of the IL-15 molecule to IL15Rα.

[0010] Furthermore, the region in the IL-15 molecule that mediates the binding of the IL-15 molecule to IL15Rα contains more than 9 amino acid residues.

[0011] In some specific embodiments, the region of the IL-15 molecule that mediates the binding of the IL-15 molecule to IL15Rα is a continuous amino acid sequence.

[0012] In some specific embodiments, the region of the IL-15 molecule that mediates the binding of the IL-15 molecule to IL15Rα is not a continuous amino acid sequence.

[0013] In some specific embodiments, the region of the IL-15 molecule that mediates the binding of the IL-15 molecule to IL15Rα comprises one or more discontinuous amino acid sites.

[0014] In some specific embodiments, the region of the IL-2 molecule that mediates the binding of the IL-2 molecule to IL2Rα is a continuous amino acid sequence.

[0015] In some specific embodiments, the region of the IL-2 molecule that mediates the binding of the IL-2 molecule to IL2Rα is not a continuous amino acid sequence.

[0016] In some specific embodiments, the region of the IL-2 molecule that mediates the binding of the IL-2 molecule to IL2Rα comprises one or more discontinuous amino acid sites.

[0017] In some specific embodiments, the IL-2 / 15 chimera is capable of reducing the affinity of the IL-2 molecule to IL2Rα.

[0018] In some specific embodiments, the IL-2 / 15 chimera is capable of eliminating the affinity of the IL-2 molecule for IL2Rα.

[0019] In some specific embodiments, the IL-2 / 15 chimera comprises:

[0020] Using loop m or a variant thereof in the region mediating the binding of IL-15 molecule to IL15Rα to replace loop M or a variant thereof in the region mediating the binding of IL-2 molecule to IL2Rα;

[0021] Using helix b or its variant in the region mediating the binding of IL-15 molecule to IL15Rα to replace helix B or its variant;

[0022] Using loop n or a variant thereof in the region mediating the binding of IL-15 molecule to IL15Rα to replace loop N or a variant thereof in the region mediating the binding of IL-2 molecule to IL2Rα;

[0023] Substituting the helix C or its variant with the helix C or its variant in the region mediating the binding of the IL-15 molecule to IL15Rα; or

[0024] One or more of loop X or its variants in the region mediating binding of IL-2 molecule to IL2Rα is replaced with loop X or its variants in the region mediating binding of IL-15 molecule to IL15Rα.

[0025] In some specific embodiments, the region mediating the binding of IL-2 molecule to IL2Rα includes loop M or a variant thereof, and the loop M comprises the sequence shown in SEQ ID NO.1.

[0026] In some specific embodiments, the region mediating the binding of IL-2 molecule to IL2Rα includes loop N or a variant thereof, and the loop N comprises the sequence shown in SEQ ID NO.5.

[0027] In some specific embodiments, the region that mediates the binding of IL-2 molecules to IL2Rα includes helix B or a variant thereof, and the helix B comprises the sequence shown in SEQ ID NO.2.

[0028] In some specific embodiments, the region mediating the binding of IL-2 molecules to IL2Rα includes loop M or its variant, helix B or its variant, wherein loop M comprises the sequence shown in SEQ ID NO.1, and helix B comprises the sequence shown in SEQ ID NO.2.

[0029] In some specific embodiments, the region mediating the binding of IL-2 molecules to IL2Rα includes helix B or its variant, loop N or its variant, wherein helix B comprises the sequence shown in SEQ ID NO.2, and loop N comprises the sequence shown in SEQ ID NO.5.

[0030] In some specific embodiments, the region mediating the binding of IL-2 molecules to IL2Rα includes loop M (loop M) or its variants, loop N (loop N) or its variants, wherein loop M comprises the sequence shown in SEQ ID NO.1, and loop N comprises the sequence shown in SEQ ID NO.5.

[0031] In some specific embodiments, the region mediating the binding of IL-2 molecules to IL2Rα comprises, from N-terminus to C-terminus, loop M or its variant, helix B or its variant, loop N or its variant, wherein loop M comprises the sequence shown in SEQ ID NO.1, helix B comprises the sequence shown in SEQ ID NO.2, and loop N comprises the sequence shown in SEQ ID NO.5.

[0032] In some specific embodiments, the region mediating the binding of IL-15 molecule to IL15Rα includes loop m or a variant thereof, and the loop m comprises the sequence shown in SEQ ID NO.8.

[0033] In some specific embodiments, the region that mediates the binding of IL-15 molecule to IL15Rα includes loop n or a variant thereof, and the loop n comprises the sequence shown in SEQ ID NO.12.

[0034] In some specific embodiments, the region that mediates the binding of IL-15 molecule to IL15Rα includes helix b or a variant thereof, and the helix b comprises the sequence shown in SEQ ID NO.9.

[0035] In some specific embodiments, the region mediating the binding of IL-15 molecule to IL15Rα includes loop m or its variant, helix b or its variant, wherein loop m comprises the sequence shown in SEQ ID NO.8, and helix b comprises the sequence shown in SEQ ID NO.9.

[0036] In some specific embodiments, the region mediating the binding of IL-15 molecule to IL15Rα includes helix b or its variant, loop n or its variant, the helix b comprises the sequence shown in SEQ ID NO.9, and the loop n comprises the sequence shown in SEQ ID NO.12.

[0037] In some specific embodiments, the region mediating the binding of IL-15 molecule to IL15Rα includes loop m or its variant, loop n or its variant, wherein loop m comprises the sequence shown in SEQ ID NO.8, and loop n comprises the sequence shown in SEQ ID NO.12.

[0038] In some specific embodiments, the region mediating the binding of IL-15 molecules to IL15Rα comprises, from N-terminus to C-terminus, loop m or its variant, helix b or its variant, loop n or its variant, wherein loop m comprises the sequence shown in SEQ ID NO.8, helix b comprises the sequence shown in SEQ ID NO.9, and loop n comprises the sequence shown in SEQID NO.12.

[0039] In some specific embodiments, the IL-2 / 15 chimera comprises replacing loop M or its variant in the region mediating the binding of IL-2 molecule to IL2Rα with loop m or its variant in the region mediating the binding of IL-15 molecule to IL15Rα.

[0040] In some specific embodiments, the IL-2 / 15 chimera comprises replacing helix B or its variant in the region mediating IL-2 molecule binding to IL2Rα with helix b or its variant in the region mediating IL-15 molecule binding to IL15Rα.

[0041] In some specific embodiments, the IL-2 / 15 chimera comprises replacing loop N or its variant in the region mediating binding of IL-2 molecule to IL2Rα with loop n or its variant in the region mediating binding of IL-15 molecule to IL15Rα.

[0042] In some specific embodiments, the IL-2 / 15 chimera includes replacing loop M or its variant in the region that mediates the binding of IL-2 molecules to IL2Rα with loop m or its variant in the region that mediates the binding of IL-15 molecules to IL15Rα, and replacing helix B or its variant in the region that mediates the binding of IL-2 molecules to IL2Rα with helix b or its variant in the region that mediates the binding of IL-15 molecules to IL15Rα.

[0043] In some specific embodiments, the IL-2 / 15 chimera includes replacing helix B or its variant in the region that mediates the binding of IL-2 molecules to IL2Rα with helix b or its variant in the region that mediates the binding of IL-15 molecules to IL15Rα, and replacing loop N or its variant in the region that mediates the binding of IL-2 molecules to IL2Rα with loop n or its variant in the region that mediates the binding of IL-15 molecules to IL15Rα.

[0044] In some specific embodiments, the IL-2 / 15 chimera includes replacing loop M or its variant in the region that mediates binding of IL-2 molecules to IL2Rα with loop m or its variant in the region that mediates binding of IL-15 molecules to IL15Rα, and replacing loop N or its variant in the region that mediates binding of IL-2 molecules to IL2Rα with loop n or its variant in the region that mediates binding of IL-15 molecules to IL15Rα.

[0045] In some specific embodiments, the IL-2 / 15 chimera includes replacing loop M or its variant in the region that mediates the binding of IL-2 molecules to IL2Rα with loop m or its variant in the region that mediates the binding of IL-15 molecules to IL15Rα, replacing helix B or its variant with helix b or its variant in the region that mediates the binding of IL-15 molecules to IL15Rα, and replacing loop N or its variant in the region that mediates the binding of IL-2 molecules to IL2Rα with loop n or its variant in the region that mediates the binding of IL-15 molecules to IL15Rα.

[0046] In some specific embodiments, the IL-2 / 15 chimera enables the modified IL-2 molecule to bind to IL15Rα or the sushi domain of IL15Rα.

[0047] In some specific embodiments, the IL-2 / 15 chimera further comprises replacing loop X or its variant in the IL-2 molecule with loop X or its variant in the IL-15 molecule, wherein loop X comprises the sequence shown in SEQ ID NO.10, and loop X comprises the sequence shown in SEQ ID NO.3.

[0048] In some specific embodiments, the IL-2 / 15 chimera further comprises replacing helix C or its variant in the IL-2 molecule with helix c or its variant in the IL-15 molecule, wherein helix c comprises the sequence shown in SEQ ID NO.11, and helix C comprises the sequence shown in SEQ ID NO.4.

[0049] In some specific embodiments, the substitutions are capable of increasing the stability of the IL-2 / 15 chimera compared to an IL-2 / 15 chimera not comprising the substitutions.

[0050] In some specific embodiments, the IL-2 / 15 chimera further comprises an amino acid replacement in the helix D region of the IL-2 molecule, and the replaced amino acid is capable of forming an aromatic ring interaction with the 43rd phenylalanine (F) in the helix b to stabilize the hydrophobic core, wherein the position of the amino acid is based on the amino acid sequence of the natural IL-15 molecule and is determined according to the EU index of KABAT numbering; the helix D comprises the sequence shown in SEQ ID NO.6.

[0051] In some specific embodiments, the amino acid sequence of the natural IL-15 molecule is shown as SEQ ID NO.13.

[0052] In some specific embodiments, the amino acid substitution comprises W121F, wherein the amino acid position is determined based on the amino acid sequence of the native IL-2 molecule according to the EU index with KABAT numbering.

[0053] In some specific embodiments, the amino acid sequence of the natural IL-2 molecule is as shown in SEQ ID NO.7.

[0054] In some specific embodiments, the IL-2 / 15 chimera comprises the sequence shown in SEQ ID NO.14.

[0055] In a specific embodiment, the IL-2 / 15 chimera may be a variant sequence comprising one or more amino acid substitutions of N77D, E76Q, I80T, and / or L81T;

[0056] and / or

[0057] Variants with one, two or three amino acids deleted from the C-terminus.

[0058] In some specific embodiments, the IL-2 / 15 chimera may be a variant sequence comprising an N77D amino acid substitution.

[0059] In a specific embodiment, the IL-2 / 15 chimera may be a variant sequence comprising an E76Q amino acid substitution.

[0060] In a specific embodiment, the IL-2 / 15 chimera may be a variant sequence comprising an I80T amino acid substitution.

[0061] In a specific embodiment, the IL-2 / 15 chimera may be a variant sequence comprising an L81T amino acid substitution.

[0062] In some specific embodiments, the IL-2 / 15 chimera comprises the sequence shown in SEQ ID NO.23-25.

[0063] In some specific embodiments, the IL-2 / 15 chimeric variant has the sequence shown in SEQ ID NO.15-18.

[0064] By mutating the IL-2 / 15 chimera, its activity is reduced, and the dosage of the fusion protein can be further increased.

[0065] In some specific embodiments, the IL15Rα receptor domain comprises a sushi domain or a variant thereof.

[0066] In some specific embodiments, the sushi domain or its variant comprises the sequence shown in SEQ ID NO.19.

[0067] In some specific embodiments, the IL15Rα receptor domain is linked to the C-terminus of the immune checkpoint antibody heavy chain.

[0068] In some specific embodiments, the immune checkpoint antibody and the IL15Rα receptor domain are covalently linked by fusion.

[0069] Furthermore, the fusion is achieved through polypeptide connection protein.

[0070] Furthermore, the polypeptide connexin comprises at least about 4 amino acids, at least about 5 amino acids, at least about 6 amino acids, at least about 7 amino acids, at least about 8 amino acids, at least about 9 amino acids, at least about 10 amino acids, at least about 11 amino acids, at least about 12 amino acids, at least about 13 amino acids, at least about 14 amino acids, at least about 15 amino acids, at least about 16 amino acids, at least about 17 amino acids, at least about 18 amino acids, at least about 19 amino acids, at least about 20 amino acids, or at least about 21 amino acids.

[0071] Furthermore, the polypeptide connexin is (G4S)n , n is an integer.

[0072] In some specific embodiments, n=2.

[0073] In some specific embodiments, the immune checkpoint antibody is an antibody targeting programmed death receptor and its ligands.

[0074] In some specific embodiments, the immune checkpoint antibody is an antibody targeting PD-1, PD-L1, CTLA-4, CD4, CD40, CD80, TNF, CD86, 4-1BB / CD137, B7-H3 / CD276, LMTK3, LAG3, TIM-3, IDO1, and TIGIT.

[0075] In some specific embodiments, the immune checkpoint antibody is an antibody targeting PD-1, PD-L1, or CTLA-4.

[0076] In some specific embodiments, the immune checkpoint antibody is a PD-1 antibody.

[0077] In some specific embodiments, the PD-1 antibody can be of any origin, for example, human, mouse, rabbit, camel, etc.

[0078] In a specific embodiment, the PD-1 antibody is murine.

[0079] Furthermore, the PD-1 antibody light chain LC is shown in SEQ ID NO.20.

[0080] Furthermore, the fusion protein of the PD-1 heavy chain HC and IL15Rα receptor domain (CD215 fragment) (sushi domain) has a sequence as shown in SEQ ID NO.21.

[0081] In a second aspect, the present invention provides a nucleic acid molecule encoding the complex of the present invention.

[0082] In a third aspect, the present invention provides a nucleic acid molecule combination, comprising a nucleic acid molecule encoding the covalently linked immune checkpoint antibody and IL15Rα receptor domain described in the present invention; and a nucleic acid molecule encoding the IL-2 / 15 chimera described in the present invention.

[0083] In a fourth aspect, the present invention provides a vector comprising the nucleic acid molecule described in the present invention, or the combination of nucleic acid molecules described in the present invention.

[0084] Furthermore, the nucleic acid molecules and / or nucleic acid molecule combinations encoding the covalently linked immune checkpoint antibodies and IL15Rα receptor domains of the present invention; and the IL-2 / 15 chimeras of the present invention may be in different vectors or in the same vector.

[0085] In some specific embodiments, the vector of the present invention comprises a first vector and a second vector, wherein:

[0086] The first vector comprises a nucleic acid molecule encoding the covalently linked immune checkpoint antibody and IL15Rα receptor domain of the present invention; and

[0087] The second vector comprises a nucleic acid molecule encoding the IL-2 / 15 chimera of the present invention.

[0088] In some specific embodiments, the vector of the present invention comprises a first vector, a second vector, and a third vector, wherein:

[0089] The first vector includes a nucleic acid molecule encoding the PD-1 light chain of the present invention;

[0090] The second vector comprises a nucleic acid molecule encoding a fusion protein of the PD-1 heavy chain and the IL15Rα receptor domain of the present invention; and

[0091] The third vector comprises a nucleic acid molecule encoding the IL-2 / 15 chimera of the present invention.

[0092] In a fifth aspect, the present invention provides a host cell, which comprises the fusion protein described in the present invention, the nucleic acid molecule or the combination of nucleic acid molecules described in the present invention, or the vector described in the present invention.

[0093] Furthermore, the host cell is a mammalian cell.

[0094] Furthermore, the host cell is selected from Chinese hamster ovary (CHO) cells, HEK293 cells, BHK cells, mouse myeloma cells (NS0 and Sp2 / 0), monkey kidney (COS) cells, VERO cells, fibrosarcoma HT-1080 cells, and HeLa cells.

[0095] In a sixth aspect, the present invention provides a pharmaceutical composition comprising the complex described in the present invention, the nucleic acid molecule or the combination of nucleic acid molecules described in the present invention, the vector described in the present invention, or the host cell described in the present invention, and a pharmaceutically acceptable excipient.

[0096] In a seventh aspect, the present invention provides use of the complex described in the present invention, the nucleic acid molecule or nucleic acid molecule combination described in the present invention, the vector described in the present invention, or the host cell described in the present invention for preparing an agent for treating cancer.

[0097] Further, the cancer can be a solid tumor or a non-solid tumor, including, for example (but not limited to), gastric cancer, small intestinal cancer, sarcoma, head and neck cancer, thymic cancer, epithelial cancer, salivary gland cancer, liver cancer, bile duct cancer, neuroendocrine tumors, gastric cancer, thyroid cancer, lung cancer, mesothelioma, ovarian cancer, breast cancer, prostate cancer, esophageal cancer, pancreatic cancer, glioma, kidney cancer (e.g., renal cell carcinoma), bladder cancer, cervical cancer, uterine cancer, vulvar cancer, penile cancer, testicular cancer, anal cancer, choriocarcinoma, colorectal cancer, oral cancer, skin cancer, Merkel cell carcinoma, carcinoma), glioblastoma, brain tumor, bone cancer, eye cancer and melanoma, multiple myeloma, malignant plasma cell tumor, Hodgkin's lymphoma, nodular lymphocyte-predominant Hodgkin's lymphoma, Kahler's disease and myeloma, plasma cell leukemia, plasma cell tumor, B-cell prolymphocytic leukemia, hairy cell leukemia, B-cell non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), follicular lymphoma.

[0098] In some specific embodiments, the cancer is colorectal cancer or prostate cancer.

[0099] In an eighth aspect, the present invention provides a method for treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the fusion protein of the present invention, the nucleic acid molecule or combination of nucleic acid molecules of the present invention, the vector of the present invention, the host cell of the present invention, or the pharmaceutical composition of the present invention.

[0100] Furthermore, the present invention provides a method for killing cancer cells in a subject in need thereof, the method comprising administering to the subject an effective amount of the fusion protein of the present invention, the nucleic acid molecule or nucleic acid molecule combination of the present invention, the vector of the present invention, the host cell of the present invention, or the pharmaceutical composition of the present invention.

[0101] Further, the present invention includes administering to the subject a second anti-cancer therapy, including a therapy selected from the following: chemotherapy, radiotherapy, surgery, an agent that activates innate immune cells, an agent that enhances the survival of NK and / or CD8+T cells, an agent that inhibits Tregs (T regulatory cells), TAMs (tumor-associated macrophages), CAFs (cancer-associated fibroblasts), or MDSCs (myeloid-derived suppressor cells), and any combination thereof.

[0102] In some specific embodiments, the cancer is colorectal cancer or prostate cancer.

[0103] Beneficial technical effects:

[0104] Through the design of the present invention, the IL-2 chimeric molecule gradually dissociates from the complex to achieve a shorter half-life, while the immune checkpoint antibody achieves a very long half-life due to the Fc domain circulating by binding to FcRn. Thus, the half-life and dosage of the two molecules can be matched with each other. BRIEF DESCRIPTION OF THE DRAWINGS

[0105] Figure 1 is a schematic diagram of the structure of the fusion protein of the present invention;

[0106] Figure 2 This is a diagram showing the efficacy of the fusion protein and its mutants in the CT-26 mouse tumor model;

[0107] Figure 3 This is a graph showing changes in body weight of the fusion protein and its mutants in the CT-26 mouse tumor model;

[0108] Figure 4 This is a high-dose pharmacodynamic diagram of the fusion protein and its mutants in the RM-1 mouse tumor model;

[0109] Figure 5 This is a graph showing the changes in body weight of the fusion protein and its mutants described in the present invention in the RM-1 mouse tumor model. DETAILED DESCRIPTION

[0110] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0111] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods. The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer.

[0112] Unless defined otherwise or clearly indicated by the context, all technical and scientific terms in the present disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs.

[0113] The fusion protein of the immune checkpoint antibody light chain and the immune checkpoint antibody heavy chain and the IL15Rα receptor domain of the present invention will form an immune checkpoint antibody molecule with the IL15Rα receptor domain fused to the C-terminus. At the same time, the IL-2 / 15 chimera (S-unit) will bind to the IL15Rα receptor domain to form a non-covalent complex L-unit, such as Figure 1 In the non-covalent complex L-unit molecule, the cytokine S-unit gradually dissociates from the L-unit molecule to achieve a shorter half-life, while the immune checkpoint antibody achieves a very long half-life due to the Fc domain circulating by binding to FcRn.

[0114] In the present invention, the term "immune checkpoint" refers to programmed death receptors and their ligands. Immune checkpoint blockade therapy based on programmed death receptors and their ligands inhibits the binding of programmed death receptors and their ligands, thereby increasing the host immune system's aggressiveness against tumor cells.

[0115] In the present invention, the term "antibody" refers to an immunoglobulin molecule that can specifically bind to targets such as carbohydrates, polynucleotides, lipids, polypeptides, etc. via at least one antigen recognition site located in the variable region of the immunoglobulin molecule. As used herein, unless otherwise specified, the term not only covers complete polyclonal or monoclonal antibodies, but also covers any antigen binding portion thereof that competes with the complete antibody for specific binding, fusion proteins including antigen binding portions, and any other modified configurations of immunoglobulin molecules including antigen recognition sites. Antigen binding portions include, for example, Fab, Fab', F(ab')2, Fd, Fv, domain antibodies (dAb, such as shark and camel antibodies), fragments including complementary determining regions (CDRs), single-chain variable fragment antibodies (scFv), maximal antibodies, minibodies, integuments, bifunctional antibodies, trifunctional antibodies, tetrafunctional antibodies, v-NARs, and bi-scFvs, and polypeptides containing at least a portion of an immunoglobulin sufficient to bind a specific antigen to a polypeptide. The antibody includes antibodies of any class, such as IgG, IgA or IgM (or a subclass thereof), and the antibody need not be of any particular class. Immunoglobulins can be assigned to different classes depending on the antibody amino acid sequence of the constant region of their heavy chains.

[0116] The "variable region" of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination. As known in the art, the variable regions of the heavy and light chains are each composed of four framework regions (FRs) connected by three complementary determining regions (CDRs), also known as hypervariable regions; and promote the formation of the antigen binding site of the antibody. If a variant of the target variable region is desired (especially with substitutions in amino acid residues outside the CDR region (i.e., in the framework region)), appropriate amino acid substitutions, preferably conservative amino acid substitutions, can be identified by comparing the target variable region with the variable regions of other antibodies (which contain CDR1 and CDR2 sequences in the same typical class as the target variable region) (Chothia and Lesk, J Mol Biol 196 (4): 901-917, 1987).

[0117] In certain embodiments, the deterministic depiction of CDRs and the confirmation of residues comprising the binding site of the antibody are achieved by analyzing the structure of the antibody and / or analyzing the structure of the antibody-ligand complex. In certain embodiments, it can be achieved by any of a variety of techniques known to those skilled in the art, such as X-ray crystallography. In certain embodiments, various analytical methods can be used to identify or approximately identify CDR regions. In certain embodiments, various analytical methods can be used to identify or approximately identify CDR regions. Examples of such methods include, but are not limited to, Kabat definitions, Chothia definitions, AbM definitions, contact definitions, and conformational definitions.

[0118] In the present invention, the term "fusion protein" refers to a first amino acid sequence connected to a second amino acid sequence, and the first amino acid sequence is not naturally connected to the second amino acid sequence in nature. Amino acid sequences that are usually present in separate proteins can be brought together in a fusion polypeptide, or amino acid sequences that are usually present in the same protein can be placed in a fusion polypeptide in a new arrangement. For example, a fusion protein is produced by chemical synthesis or by generating and translating a polynucleotide in which the peptide regions are encoded in a desired relationship. The fusion protein can include a second amino acid sequence that is connected to the first amino acid sequence by a peptide, polypeptide or peptide bond, a covalent bond, a non-peptide bond or a non-covalent bond.

[0119] In the present invention, the term "C-terminus" generally refers to one of the two ends of a polypeptide chain, and the amino acid residue at this end carries a free α-carboxyl group (-COOH).

[0120] In the present invention, the term "N-terminus" generally refers to one of the two ends of a polypeptide chain, the amino acid residue at this end carrying a free α-amino group (-NH2).

[0121] In the present invention, the term "identity" refers to the number of identical matching positions shared by the sequences over the comparison window, taking into account additions or deletions that must be introduced to achieve optimal alignment of the two sequences.

[0122] In the present invention, the term "polynucleotide" or "nucleic acid" refers to a nucleotide chain of any length, and includes DNA and RNA. The nucleotides may be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogs or any substrate that can be incorporated into the chain by DNA or RNA polymerase. The polynucleotide may include modified nucleotides, such as methylated nucleotides and their analogs.

[0123] In the present invention, the term "variant" or "mutant" refers to the substitution, deletion or insertion of several amino acids in the amino acid sequence of a protein or polypeptide. Those skilled in the art know that conservative mutations of amino acids often do not affect the activity of the protein or polypeptide. Those skilled in the art also know that truncation of 1-3 amino acids at the terminal group of a protein or polypeptide usually does not affect the activity of the protein or polypeptide.

[0124] In the present invention, the term "effective dose" or "effective amount" refers to an amount sufficient to affect any one or more beneficial or desired results. More specifically, an effective amount prevents, alleviates or improves the symptoms of a disease and / or prolongs the survival of a treated subject. For preventive use, beneficial or desired results include eliminating or reducing the risk of a disease, reducing the severity of a disease, or delaying the onset of a disease, wherein a disease includes the biochemical, tissue and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes presented during the development of the disease. For therapeutic use, beneficial or desired results include clinical results, such as reducing one or more symptoms of a disease.

[0125] In the present invention, the term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any material that allows the ingredient to retain biological activity and does not react with the subject's immune system when combined with the active ingredient. Examples include, but are not limited to, any of the standard pharmaceutical carriers, such as phosphate buffered saline solution, water, emulsions (such as oil / water emulsions), and various types of wetting agents. Preferred diluents for aerosol or parenteral administration are phosphate buffered saline (PBS) or normal saline (0.9%). Compositions including such carriers are formulated by well-known conventional methods (see, for example, Remington's Pharmaceutical Sciences, 18th edition, A. Gennaro, ed., Mack Publishing Co., Easton, PA, 1990; and Remington, The Science and Practice of Pharmacy 20th edition, Mack Publishing, 2000).

[0126] Example 1. Gene cloning and protein expression

[0127] The present invention entrusts Suzhou Jinweizhi Biotechnology Co., Ltd. to synthesize plasmids capable of encoding and expressing Anti-mouse PD-1 light chain LC (numbered PM900, SEQ ID NO: 20), Anti-mouse PD-1 heavy chain HC and CD215 fragment fusion protein (numbered PM1056, SEQ ID NO: 21) and modified IL-2 molecule (cytokine S-unit molecule) (numbered PM619, SEQ ID NO: 14) in Expi293 cells, and point mutations are performed according to the operating method mentioned in the Molecular Cloning Experiment Guide to obtain plasmids capable of expressing S-unit molecule mutants (the mutation sites are N77D, E76Q, I80T, L81T (SEQ ID NO: 15-18), and the four mutants are numbered PM1057, PM1058, PM1059, PM1060). PM900 and PM1056 were co-expressed with plasmids PM619, PM1057, PM1058, PM1059 and PM1060, respectively, to obtain the protein mPD-1-S-unit and its mutants mPD-1-S-unit-1057, mPD-1-S-unit-1058, mPD-1-S-unit-1059 and mPD-1-S-unit-1060.

[0128] The inventors also found in their research that the C-terminus of the S-unit molecule or its mutant may have a deletion mutation of 1-3 amino acids, but it does not affect its activity.

[0129] According to the operation method mentioned in the Molecular Cloning Experiment Guide, DH10B was transformed and the bacterial culture was cultured for transient expression plasmid preparation. According to the operation method mentioned in the Qiagen Mini-prep Kit and Qiagen Endofree Maxi-prep Kit, the plasmid used for expression was prepared. Expression was performed according to the standard operation procedure for transient expression. Specifically, according to the volume required for transfection, fresh passages of 2.0-2.5×10 6Prepare plasmid reagent (plasmid 1μg / mL + Opti-MEMTM 33.3μL / mL, if multiple plasmids are co-expressed, the default is equal mass ratio, this ratio can be optimized) and transfection reagent (PEI 2μg / mL + Opti-MEMTM 33.3μL / mL) and place at room temperature for 10 minutes, then add the transfection reagent dropwise to the plasmid reagent, incubate at room temperature for 10 minutes, add the mixture to the cell suspension, and culture it in a shaker at 115rpm, 36.8℃, 5% CO2. After 24 hours, add 50×KT Feed to a final concentration of 1×, and then continue to culture in a shaker for 5-7 days, centrifuge at 8500rpm for 15min to collect the cell supernatant, and then purify it.

[0130] Example 2: Purification and analysis of mPD-1-S-unit and its mutants

[0131] The purification process of all proteins in the present invention uses a two-step purification including Protein A affinity chromatography, ultrafiltration concentration and liquid exchange, and the specific operation steps are: add 4M sodium chloride to the centrifuged cell culture supernatant to a final concentration of 0.2M sodium chloride, and adjust the pH to 7.5 with 1M Tris-Cl buffer. Load the prepared sample onto AT Protein A Diamond (Borgron) that has been pre-equilibrated with 2×PBS pH7.4, and rinse with equilibrium buffer until the baseline is stable to remove most of the non-specifically bound impurities (such as host proteins, host DNA, etc.). Finally, elute with an elution buffer containing 100mM glycine, 10mM sodium chloride, pH3.2, and quickly adjust the pH value of the eluent to 8.0. The purity of the final product is determined by SDS-PAGE analysis, and the specific results are shown in Table 1 below.

[0132] Table 1. Concentration and purity of purified proteins used in the present invention

[0133]

[0134]

[0135] Example 3. Cellular activity assay of mPD-1-S-unit and its mutants

[0136] The HEK Blue cell line used in the present invention to detect the cytological activity of mPD-1-S-unit and its mutants was constructed by our company. The cell line can simultaneously express CD215 (IL-15Rα), CD122 (IL-15Rβ) and CD132 (IL-15Rγ) proteins. When the signal pathway is activated, the activation degree of the signal pathway can be determined by detecting the absorption at 620nm. The specific operation steps include: first, wash the HEK Blue cell line twice with PBS, add 10mL of culture medium, scrape the cells with a cell scraper, and adjust the cell density to 5×10 after counting. 5 cell / mL, and add 100μL / well to a flat-bottom 96-well culture plate, and incubate in a 37℃, 5% CO2 incubator for 2h. Secondly, dilute the sample to be tested to a starting concentration of 100nM, and then perform a 5-fold serial dilution, a total of 10 points, 100μL / well added to the plated cells, and each sample is repeated 3 times. Finally, place the 96-well plate in a 37℃, 5% CO2 incubator for 20h, take 20μL of supernatant and add it to a new 96-well plate, and add 180μL QUANTI-Blue to each well. TM Solution (Invivogen), incubate at 37°C for 2 h, and use a microplate reader to detect the expression level of SEAP at 620 nm, fit the curve, and calculate the EC50 value. The specific results are shown in Table 2.

[0137] Table 2. Cellular activity assay of mPD-1-S-unit and its mutants

[0138]

[0139]

[0140] From the above-mentioned cytological activity detection of mPD-1-S-unit and its mutants based on HEK Blue cell line, it can be found that by using different mutation strategies, the cytological activity of mPD-1-S-unit mutants decreased by 6 to 50 times relative to the wild-type mPD-1-S-unit. The reduction in the relative activity of cytokines helps to further reduce the toxicity of mPD-1-S-unit fusion protein and increase its dosage, thereby achieving better efficacy.

[0141] Example 4. Determination of the half-life of the intact molecule of Fc-L-unit

[0142] In the present invention, Fc-L-unit is composed of two parts, namely S-unit and the CD215 fragment part of fusion Fc. Only when the two form a complete complex can they exercise normal function. Therefore, in the ELISA experiment in this embodiment, an antibody is used to capture the S-unit part, and another antibody is used to detect the Fc part to achieve the purpose of detecting the complete molecule of Fc-L-unit. The present invention measures the half-life test of Fc-L-unit complete molecule with 24 BALB / c mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.), half male and half female, with a dosage of 1.5 mg / kg, and a single intravenous injection of Fc-L-unit, with a dosage of 5 mL / kg. Collect serum samples of all animals before administration (D-1), immediately after the end of administration (±1min), and 20min, 40min, 1h, 2h, 3h, 4h, 8h, 24h, and 48h after the start of administration. Four animals of each sex in each group are used as a team, and each team is used alternately, and 4 / sex are arranged at each blood collection point. After blood sample collection, it was transferred to a centrifuge tube (without anticoagulation), then centrifuged at 3000×g for 10 min at 4°C and stored below -60°C.

[0143] The developed ELISA method was used to determine the content of Fc-L-unit molecules in mouse serum. The pharmacokinetic parameters of the drug administration group were calculated using the non-compartmental model method (NCA) of WinNonlin 8.0 software. The results are shown in Table 3.

[0144] Table 3. Calculation results of pharmacokinetic parameters

[0145]

[0146] From this experiment, we can know that the complete molecule of Fc-L-unit is metabolized quickly in mice, and S-unit disappears quickly after dissociation from CD215. Its complete molecule half-life is less than two hours. The short half-life can avoid excessive immune activation toxicity and avoid the problem of too low dosage after fusion with PD-1 antibody. At the same time, the advantage of this molecular structure is that the half-life of the active ingredient S-unit is not affected by other structures in the molecule, and will not be changed by factors such as fusion with PD-1 antibody, which is conducive to solving the problem of the difference between the half-life of PD-1 antibody and the half-life of cytokines in the mPD-1-S-unit molecule.

[0147] Example 5. Efficacy determination of mPD-1-S-unit and its mutants in CT26 mouse colon cancer tumor model

[0148] In this example, CT26 tumor cells belonging to mouse colon cancer were inoculated subcutaneously on the right back of BALB / c female mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) at a cell inoculation volume of 5×10 5 / mouse. When the tumor grows to 77mm 3 The animals were divided into groups and administered at about 1:10 pm, with a total of 5 groups, including a negative control group, an IL-2 treatment group, an anti-PD-1 treatment group, an mPD-1-S-unit treatment group, and an mPD-1-S-unit-1058 treatment group, with 6 animals in each group. The IL-2 treatment group was administered at a dose of 10 μg / kg, and the other groups were administered at a dose of 5 mg / kg, once a week for two weeks, by intraperitoneal injection. The animal weight and tumor volume were examined.

[0149] The tumor volume was measured twice a week using a vernier caliper and the mice were weighed using an electronic balance. The long and short diameters of the tumor were measured and the volume was calculated using the following formula: tumor volume TV (mm 3 )=0.5×long diameter(mm)×short diameter(mm) 2 Tumor growth inhibition rate TGITV% = (1-T / C) × 100%, T / C = treatment group RTV / control group RTV.

[0150] At the end of the experiment, the animals were euthanized, and the tumor growth inhibition rate was calculated and statistically analyzed. Specific data are shown in Table 4.

[0151] Table 4. Tumor inhibition rate and statistical difference analysis on day 19

[0152]

[0153] In this animal efficacy experiment, both mPD-1-S-unit and mPD-1-S-unit-1058 showed good anti-mouse colon tumor cell activity, and the tumor volume continued to decrease relative to the negative control ( Figure 2 In this experiment, the animals gained weight normally and no drug-related side effects were observed. The effects of mPD-1-S-unit and mPD-1-S-unit-1058 on the weight of mice were similar to those of anti-mouse PD-1 antibodies alone, and no additional toxicity was observed. Figure 3 ).

[0154] Example 6. Efficacy determination of mPD-1-S-unit and its mutants in RM-1 mouse prostate cancer tumor model

[0155] In this example, RM-1 tumor cells belonging to mouse prostate cancer were inoculated subcutaneously on the right back of C57BL / 6J female mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) at a cell inoculation volume of 1×106 / mouse. When the tumor grows to 87mm 3 The animals were divided into groups and administered at about 1:10 pm, with a total of 5 groups, including a negative control group, an anti-PD-1 antibody treatment group, an Fc-L-unit molecule treatment group, an mPD-1-S-unit treatment group, and an mPD-1-S-unit-1058 treatment group, with 6 animals in each group. The anti-PD-1 treatment group was administered at a dose of 20 mg / kg, the Fc-L-unit molecule treatment group was administered at a dose of 3 mg / kg, and the mPD-1-S-unit treatment group and the mPD-1-S-unit-1058 treatment group were administered at a dose of 10 mg / kg. The drugs were administered once a week for two weeks by intraperitoneal injection. The animal weight and tumor volume were examined.

[0156] The tumor volume was measured twice a week using a vernier caliper and the mice were weighed using an electronic balance. The long and short diameters of the tumor were measured and the volume was calculated using the following formula: tumor volume TV (mm 3 )=0.5×long diameter(mm)×short diameter(mm) 2 Tumor growth inhibition rate TGITV% = (1-T / C) × 100%, T / C = treatment group RTV / control group RTV.

[0157] At the end of the experiment, the animals were euthanized and the tumor growth inhibition rate was calculated. Specific data are shown in Table 5.

[0158] Table 5. Tumor inhibition rate on day 21

[0159] Drug Name Tumor inhibition rate on day 21 (%) Anti-PD-1 antibodies 4.21 Fc-L-unit molecule 28.26 mPD-1-S-unit 62.78 mPD-1-S-unit-1058 39.73

[0160] In this animal experiment, the invention used the RM-1 mouse model and a higher dosage method to test the efficacy and toxicity of mPD-1-S-unit and mPD-1-S-unit-1058 in this animal model. In this experiment, both mPD-1-S-unit and mPD-1-S-unit-1058 showed better efficacy than single PD-1 antibody or Fc-L-unit ( Figure 4 ), and the weight changes of mice were similar to those of PD-1 antibody and Fc-L-unit molecule ( Figure 5 ), in addition, in this group of experiments, except for one mouse death in the solvent control group, no mouse death was observed in other groups, which indicates that even at high doses, mPD-1-S-unit and mPD-1-S-unit-1058 do not increase toxicity relative to PD-1 antibodies.

[0161] Sequence information:

[0162]

[0163]

[0164]

Claims

1. A complex of an antibody and IL-2, comprising: Covalently linked immune checkpoint antibodies and IL15Rα receptor domains, and An IL-2 / 15 chimera or variant thereof non-covalently complexed with an IL15Rα receptor domain.

2. The composite body according to claim 1, characterized in that The IL-2 / 15 chimera or variant thereof includes: replacing loop M (SEQ ID NO: 1) or its variant in the region mediating the binding of IL-2 molecules to IL2Rα with loop m (SEQ ID NO: 8) or its variant in the region mediating the binding of IL-15 molecules to IL15Rα; Substituting helix B (SEQ ID NO: 2) or its variant with helix b (SEQ ID NO: 9) or its variant in the region mediating the binding of IL-15 molecule to IL15Rα; Substituting loop X (SEQ ID NO: 3) or its variant in the region mediating the binding of IL-2 molecules to IL2Rα with loop X (SEQ ID NO: 10) or its variant in the region mediating the binding of IL-15 molecules to IL15Rα; Substituting helix C (SEQ ID NO: 4) or its variant with helix c (SEQ ID NO: 11) or its variant in the region mediating the binding of IL-15 molecule to IL15Rα; or Substituting one or more of loop N (SEQ ID NO: 5) or its variants in the region mediating the binding of IL-2 molecules to IL2Rα with loop n (SEQ ID NO: 12) or its variants in the region mediating the binding of IL-15 molecules to IL15Rα; Optionally, an amino acid substitution is performed in the helix D region of the IL-2 molecule, and the substituted amino acid can form an aromatic ring interaction with the 43rd phenylalanine (F) in the helix b to stabilize the hydrophobic core, wherein the position of the amino acid is based on the amino acid sequence of the natural IL-15 molecule and is determined according to the EU index of KABAT numbering; the helix D comprises the sequence shown in SEQ ID NO.6; The sequence of the wild-type IL-2 molecule is shown in SEQ ID NO:

7.

3. The composite body according to claim 2, characterized in that The IL-2 / 15 chimera or its variant comprises the sequence shown in SEQ ID NO.

14.

4. The composite body according to claim 2, characterized in that The IL-2 / 15 chimera or variant thereof is a variant sequence comprising one or more amino acid substitutions of N77D, E76Q, I80T, and / or L81T; and / or Variants with one, two or three amino acids deleted from the C-terminus.

5. The composite body according to claim 4, characterized in that The IL-2 / 15 chimera or variant thereof has a sequence as shown in SEQ ID NO. 15-18 or 23-25.

6. The composite body according to claim 1, characterized in that The IL15Rα receptor domain includes a sushi domain or a variant thereof.

7. The composite body according to claim 6, characterized in that The sushi domain or its variant comprises the sequence shown in SEQ ID NO.

19.

8. The composite body according to claim 1, characterized in that The IL15Rα receptor domain is linked to the C-terminus of the immune checkpoint antibody heavy chain.

9. The composite body according to claim 8, characterized in that The immune checkpoint antibody and the IL15Rα receptor domain are covalently linked by fusion.

10. The composite body according to claim 9, characterized in that The fusion is achieved via a polypeptide linker protein.

11. The composite body according to claim 10, characterized in that The polypeptide connecting protein is (G4S) n , n is an integer.

12. The composite according to any one of claims 1 to 11, characterized in that: The immune checkpoint antibodies are antibodies targeting programmed death receptors and their ligands.

13. The composite body according to claim 12, characterized in that The immune checkpoint antibody is a PD-1 antibody.

14. The composite body according to claim 13, characterized in that The PD-1 antibody light chain LC is shown in SEQ ID NO.

20.

15. The composite body according to claim 13, characterized in that The fusion protein of the PD-1 heavy chain HC and IL15Rα receptor domain has a sequence as shown in SEQ ID NO.

21.

16. A nucleic acid molecule comprising a protein encoding the complex according to any one of claims 1 to 15.

17. A nucleic acid molecule combination, comprising a nucleic acid molecule encoding the covalently linked immune checkpoint antibody and IL15Rα receptor domain as described in any one of claims 1 to 15; and a nucleic acid molecule encoding the IL-2 / 15 chimera as described in any one of claims 1 to 15.

18. A vector comprising the nucleic acid molecule according to claim 16, or the nucleic acid molecule combination according to claim 17.

19. A host cell comprising the complex according to any one of claims 1 to 15, the nucleic acid molecule according to claim 16, the nucleic acid molecule combination according to claim 17, or the vector according to claim 18.

20. A pharmaceutical composition comprising: The complex according to any one of claims 1 to 15, the nucleic acid molecule according to claim 16, the nucleic acid molecule combination according to claim 17, the vector according to claim 18, or the host cell according to claim 19, and Pharmaceutically acceptable excipients.

21. Use of the complex according to any one of claims 1 to 15, the nucleic acid molecule according to claim 16, the nucleic acid molecule combination according to claim 17, the vector according to claim 18, or the host cell according to claim 19 for preparing an agent for treating cancer.

22. The use according to claim 21, characterized in that The cancer is colorectal cancer, prostate cancer.

Images